Mainz Biomed and OncoVanguard8 Enter into Agreement to Bring ColoAlert to South America

Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostics company specializing in early cancer detection, announced on November 18, 2025 that it has signed a Memorandum of Understanding (MOU) with OncoVanguard8, a Peruvian‑based distributor of oncology innovations. The agreement sets the stage for the introduction of the company’s flagship DNA‑based colorectal cancer screening test, ColoAlert®, into the South American markets of Peru, Colombia and Ecuador, with an initial launch in Peru. Colorectal cancer remains one of the most common—and significantly preventable—types of cancer worldwide. In the three target markets alone, roughly 17,000 new cases are diagnosed each year, underscoring the urgency for enhanced early detection technologies. The rollout of ColoAlert is seen as a major step toward increasing screening participation rates, enabling earlier diagnosis, and supporting public‑health efforts in the region to reduce colorectal cancer mortality and improve long‐term population health. Under the MOU, Mainz Biomed and OncoVanguard8 have outlined the commercial, legal and regulatory framework, along with a go‑to‑market strategy for the initial territory. They intend to finalize a full distribution agreement in the coming weeks. About Mainz Biomed: The company develops ready‑to‐market molecular genetic diagnostics for life‑threatening conditions. ColoAlert, a non‑invasive early‐detection test for colorectal cancer, is already marketed across Europe. Its pipeline also includes PancAlert, an early pancreatic cancer screening test based on multiplex PCR detection of biomarkers in blood and stool samples. About OncoVanguard8: Headquartered in Lima, Peru, OncoVanguard8 acts as a strategic partner to insurers, hospitals and healthcare networks in Peru, Colombia and Ecuador, with a mission to bridge the technological gap in cancer prevention and early detection. Forward‐looking statements caution that actual results may differ materially from projections due to factors such as regulatory changes, market acceptance and other uncertainties. #ColorectalCancerScreening #HealthcareInnovationLatAm #MainzBiomed #OncoVanguard8 #SlimScan #GrowthStocks #CANSLIM